Agilent Technologies and A2 Technologies have signed a definitive agreement for Agilent to acquire specific assets of A2 Technologies. The acquisition is reported to include substantially all of A2 Technologies' intellectual property, technology, employees and its spectroscopy product portfolio.
Agilent Technologies and A2 Technologies have signed a definitive agreement for Agilent to acquire specific assets of A2 Technologies. The acquisition is reported to include substantially all of A2 Technologies’ intellectual property, technology, employees and its spectroscopy product portfolio.
“A2 Technologies’ products, technology and people are a great fit with Agilent,” said Mike McMullen, president of the company’s chemical analysis group. “We set out to grow our spectroscopy business, which we acquired this past year when Varian joined us, so we can offer customers an even wider range of the industry’s best solutions. Adding A2 Technologies’ cutting-edge, patented technology and top talent is a major move in this direction.”
A2 Technologies, headquartered in Danbury, Connecticut, USA, focuses on Fourier transform infrared (FT‑IR) technology for lab and field use. The company designs, develops and manufactures FT-IR spectrometers for routine analysis and out-of-lab applications in the petrochemical, environmental, aerospace, art conservation, academia and geosciences markets.
“We are very excited about joining the Agilent team as we believe it will greatly benefit our employees and customers,” said Jon Frattaroli, CEO and co-founder of A2 Technologies. “For A2 Technologies, it will mean access to the many resources of Agilent, including their global distribution and support networks, as well as their innovative technology platforms.”
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.